한글목차

세계의 인간 인슐린 제제 시장은 2025년에 570억 4,000만 달러로 추정되며, 2032년에는 1,023억 5,000만 달러에 달할 것으로 예측되며, 2025-2032년에 CAGR 8.7%로 성장할 것으로 예측됩니다.

도표. 2025년 지역별 인간 인슐린 제제 시장 점유율(%)

세계 인슐린 제제 시장은 전 세계에서 당뇨병 유병률이 증가함에 따라 지난 수년간 안정적인 성장세를 보이고 있습니다. 인간 인슐린 제제는 일반 인간 인슐린을 생합성하여 만든 것으로, 당뇨병 치료 및 관리에 사용됩니다. 국제당뇨병연맹이 발표한 데이터에 따르면 2020년에는 약 4억 6,300만 명의 성인이 당뇨병을 앓고 있으며, 2045년까지 7억 명으로 늘어날 것으로 예상됩니다. 당뇨병 인구 증가, 인슐린 요법에 대한 인식 증가, 인슐린 펜 및 펌프와 같은 혁신적인 인슐린 제제 전달 시스템의 도입은 전 세계에서 인간 인슐린 제제에 대한 수요를 증가시킬 것으로 예상됩니다.

시장 역학

인슐린 제제 세계 시장 성장은 주로 비만, 좌식 생활습관, 고령화, 유전적 요인으로 인한 당뇨병 유병률 증가가 주도하고 있으며, WHO에 따르면 당뇨병은 주요 사망 원인 중 하나이며, 매년 150만 명이 당뇨병으로 사망하는 것으로 추정되고 있습니다. 인슐린 요법에 대한 인식 증가와 인슐린 펌프 및 펜과 같은 인슐린 투여를 위한 다양한 혁신적인 약물전달 옵션은 시장 성장을 가속할 수 있습니다. 그러나 인간 인슐린 제제의 높은 가격은 시장 성장을 저해하는 요인으로 작용할 수 있습니다. 바이오시밀러 인슐린 제제의 개발은 시장 진출기업에게 유리한 성장 기회를 제공합니다.

본 조사의 주요 특징

• 세계의 인간 인슐린 제제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR%)을 게재하고 있습니다.
• 또한 다양한 부문에 걸친 잠재적인 매출 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 인간 인슐린 제제 시장의 주요 업체를 프로파일링합니다.
• 주요 기업에는 Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis, Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V. 등이 포함됩니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 인간 인슐린 제제 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 인간 인슐린 제제 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요
• COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 제조업체 매출
• 인수와 제휴 시나리오
• 제품 발매/승인
• 자금조달과 투자
• PEST 분석
• Porter의 산업 분석

제4장 세계의 인간 인슐린 제제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 구상
• 시장에 대한 COVID-19의 영향

제5장 세계의 인간 인슐린 제제 시장, 제품 유형별, 2020-2032년(10억 달러)

• 서론
• 인간 인슐린
• 기초 인슐린
• Bolus Insulin
• 혼합 인슐린
• 바이오시밀러 인슐린

제6장 세계의 인간 인슐린 제제 시장, 유형별, 2020-2032년(10억 달러)

• 서론
• 단시간 작용형
• 장시간 작용형

제7장 세계의 인간 인슐린 제제 시장, 용도별, 2020-2032년(10억 달러)

• 서론
• 1형 당뇨병
• 2형 당뇨병

제8장 세계의 인간 인슐린 제제 시장, 지역별, 2020-2032년(10억 달러)

• 서론
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan NV

제10장 애널리스트의 권장사항

• 운명의 수레바퀴
• COM(Coherent Opportunity Map)

제11장 참고 문헌과 조사 방법

• 참고 문헌
• 조사 방법

영문목차

Global Human Insulin Drug Market is estimated to be valued at USD 57.04 Bn in 2025 and is expected to reach USD 102.35 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Figure. Human Insulin Drug Market Share (%), By Region 2025

Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2020 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.

Market Dynamics:

Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global human insulin drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human insulin drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this includes Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis , Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human insulin drug market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market

Detailed Segmentation-

• By Product Type:
  • Human Insulin
  • Basal Insulin
  • Bolus Insulin
  • Insulin Combinations
  • Biosimilar Insulins
• By Type:
  • Short Acting
  • Long Acting
• BY Application:
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Human Insulin Drug Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Human Insulin Drug Market, By Product Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Human Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Basal Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bolus Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Insulin Combinations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biosimilar Insulins
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Human Insulin Drug Market, By Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Short Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Long Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Human Insulin Drug Market, By Application, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Type 1 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Type 2 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Human Insulin Drug Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2032, (USD Bn)
  • Forecast, and Y-o-Y Growth, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Sanofi*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Biocon Limited
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wockhardt Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SEDICO
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Exir
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aventis
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan N.V.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact